reportingrisk.com← the monitorSEC reporting failures, scored and checked against what happened next

Or browse all companies A–Z.

Akari Therapeutics Plc

AKTX · Nasdaq

1 reporting failure in the last 12 months

Companies at this level ended the following year delisted, bankrupt, restated or silent 9.2% of the time, against 4.0% for companies with a clean record.

$15Mpublic float
2026-05-18most recent failure

Score over time

01232024202520262024-10-01 · score 12024-08-15 filed late (10-Q) · accounts not ready2025-01-01 · score 22024-11-15 filed late (10-Q) · acquisition or merger2024-08-15 filed late (10-Q) · accounts not ready2025-04-01 · score 32025-03-31 filed late (10-K) · acquisition or merger2024-11-15 filed late (10-Q) · acquisition or merger2024-08-15 filed late (10-Q) · accounts not ready2025-07-01 · score 32025-03-31 filed late (10-K) · acquisition or merger2024-11-15 filed late (10-Q) · acquisition or merger2024-08-15 filed late (10-Q) · accounts not ready2025-10-01 · score 22025-03-31 filed late (10-K) · acquisition or merger2024-11-15 filed late (10-Q) · acquisition or merger2026-01-01 · score 12025-03-31 filed late (10-K) · acquisition or merger2026-07-01 · score 12026-05-18 filed late (10-Q)2026-10-01 · score 12026-05-18 filed late (10-Q)

Hover or tap a dot to see the filings behind that score.

Why they said they were late

The Quarterly report on Form 10-Q for the period ended March 31, 2026 (“Quarterly Report”) of Akari Therapeutics, Plc (the “Company”) could not be filed on schedule due to management and counsel devoting substantial time and resources to matters relating to the Company’s previously announced upcoming public offering and the disclosures related thereto. The Company expects to be in a position to file the Quarterly Report within the five-day extension provided by Rule 12b-25 under the Securities Exchange Act of 1934

NT 10-Q, filed 2026-05-18

What it filed

2026-05-18filed late (10-Q) SEC →

The Quarterly report on Form 10-Q for the period ended March 31, 2026 (“Quarterly Report”) of Akari Therapeutics, Plc (the “Company”) could not be filed on schedule due to management and counsel devoting substantial time and resources to matters relating to the Company’s previously announced upcoming public offering and the disclosures related thereto. The Company expects to be in a position to file the Quarterly Report within the five-day extension provided by Rule 12b-25 under the Securities Exchange Act of 1934

2025-03-31filed late (10-K)acquisition or merger SEC →

Akari Therapeutics, plc (the “Company”) will be unable to file its Annual Report on Form 10-K for the year ended December 31, 2024 (the “Form 10-K”) within the prescribed time period without unreasonable effort or expense. The Company requires additional time to complete its financial statement close procedures and finalize its financial statements to be included in the Form 10-K due primarily to the accounting for the business combination that occurred on November 14, 2024, and other accounting items, not yet being completed. For these reasons, the Company needs additional time to complete its financial statements and other disclosures in the Form 10-K. The Company currently expects to file its Form 10-K within the fifteen calendar day extension provided by Rule 12b-25

2024-11-15filed late (10-Q)acquisition or merger SEC →

The Quarterly report on Form 10-Q for the period ended September 30, 2024 (“Quarterly Report”) of Akari Therapeutics, Plc (the “Company”) could not be filed on schedule due to the time and resources required for the Company to complete the closing of the Company’s previously announced merger with Peak Bio, Inc and the disclosures related thereto. The Company expects to be in a position to file the Quarterly Report within the five-day extension provided by Rule 12b-25 under the Securities Exchange Act of 1934

2024-08-15filed late (10-Q)accounts not ready SEC →

The Quarterly report on Form 10-Q for the period ended June 30, 2024 (“Quarterly Report”) of Akari Therapeutics, Plc (the “Company”) could not be filed on schedule due to additional time required for the Company to prepare and compile its financial information. The Company expects to be in a position to file the Quarterly Report on or before August 19, 2024, the prescribed due date under the five calendar day extension period provided under Rule 12b-25 under the Securities Exchange Act of 1934

About this score

reportingrisk.com scores every active US filer on three things a company tells the SEC about itself: late-filing notices on Form NT, 8-K item 4.02 (past accounts declared unreliable) and 4.01 (auditor changes). 1,012 are flagged today.

Every score is frozen and checked twelve months later. Across 91,452 of them, a company scoring 4 or more ended that year delisted, bankrupt, restated or silent 17.2% of the time, against 4.0% for a clean record. Scores before 2026-09-27 were reconstructed from the filing history as it stood at each date, so the record is a backtest rather than years of live calls.

See the ledger → Every company the score flagged that later failed, what it told the SEC on the way down, and the ones it missed.

Every item above is a filing this company made with the SEC.
Snapshot 2026-11-04 · data from SEC EDGAR (public domain) · not investment advice

reportingrisk.com← back to the monitorAll companies A-Z · RSS · found an error? hello@reportingrisk.com